3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Squamous Cell Carcinoma of Head and Neck
4
Pancreatic Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Hepatocellular
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Melanoma
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Neuroendocrine
1
Anophthalmia with pulmonary hypoplasia
1
Interventions
pembrolizumab
44
Gemcitabine
23
Nivolumab
21
enfortumab vedotin
20
Cisplatin
17
avelumab
16
Magnetic Resonance Spectroscopy
16
Carboplatin
14
atezolizumab
13
Specimen Handling
12
Docetaxel
11
sacituzumab govitecan
9
Paclitaxel
8
Ipilimumab
8
durvalumab
6
Mitomycin
5
Fluorodeoxyglucose F18
5
cabozantinib
4
Taxes
4
toripalimab
3
pemigatinib
3
erdafitinib
3
X-Rays
3
Radiosurgery
3
Platinum
3
Pemetrexed
3
Immunoglobulin G
3
CTLA-4 Antigen
3
Biopsy
3
ALT-803
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
budigalimab
×
1 year
×
Clear all
NCT06632951
2025-08-11
LIVIGNO-3
AbbVie
Phase 2
Active not recruiting
150 enrolled